Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b Study of Pidnarulex and Trastuzumab Deruxtecan in Patients With HER2 Expressing Solid Tumors

NCT07137416 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT07137416
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07137416 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b Study of Pidnarulex and Trastuzumab Deruxtecan in Patients With HER2 Expressing Solid Tumors
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Recruiting
Start date
October 5, 2026
Completion date
January 10, 2028
Enrollment
36 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

anatomic stage iii breast cancer ajcc v8, anatomic stage iv breast cancer ajcc v8, invasive breast carcinoma, locally advanced breast carcinoma, metastatic breast carcinoma, metastatic her2-low breast carcinoma, metastatic her2-positive breast carcinoma, metastatic hormone receptor-positive breast carcinoma, metastatic malignant solid neoplasm, metastatic triple-negative breast carcinoma, unresectable breast carcinoma, unresectable her2-low breast carcinoma, unresectable her2-positive breast carcinoma, unresectable hormone receptor-positive breast carcinoma, unresectable malignant solid neoplasm, unresectable triple-negative breast carcinoma